Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Palmieri, Giuseppe ^a   Satriano, Sabrina M R ^b   Budroni, Mario ^c   Cossu, Antonio ^c   Tanda, Francesco ^c   Canzanella, Sergio ^d   Caracò, Corrado ^b   Simeone, Ester ^b   Daponte, Antonio ^b   Mozzillo, Nicola ^b   Comella, Giuseppe ^b   Castello, Giuseppe ^b   Ascierto, Paolo A ^b  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Azienda USL 1   (Italy)

^d Associazione House Hospital Onlus   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MELAN A; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; OCCULT CANCER; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; UNIVARIATE ANALYSIS; VISCERAL METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33751401113     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-266     Document Type: Article

References (34)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001, 19:3622-34.
2. Dutcher JP: The prognostic role of detection of circulating melanoma cells in the blood. J Clin Oncol 2003, 21:757-9.
3. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 1998, 280:1410-5.
4. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-9.
5. Brossart P, Schmier JW, Kruger S, Willhauck M, Scheibenbogen C, Mohler T, Keilholz U: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995, 55:4065-8.
6. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995, 2:155-9.
7. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DS: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997, 57:1371-6.
8. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLAA2 melanomas. J Exp Med 1993, 178:489-95.
9. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996, 88:590-4.
10. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997, 15:2826-31.
11. Glaser P, Rass K., Seiter S, Hauschild A, Christophers E, Tilgen W: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 1997, 15:2818-25.
12. Reinhold U, Ludtke-Handiery HC, Schnautz S, Kreysel HW, Abken H: The analysis of tyrosinase specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997, 108:166-9.
13. Aubin F, Chtourou M, Teyssier JR, Laubriet A, Mougin CH, Blanc D, Humbert P: The detection of tyrosinase mRNA in the peripheral blood of stage 1 melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000, 10:113-8.
14. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13:2109-16.
15. Palmieri G, Strazzullo M, Ascierto PA, Satriano SMR, Daponte A, Castello G: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol 1999, 17:304-11.
16. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C: Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Brit J Dermatol 1999, 141:30-6.
17. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A, Atzpodien J, Buer J: Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res 2000, 10:355-62.
18. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS: The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 2001, 158:78-92.
19. Palmieri G, Ascierto PA, Perrone F, Satriano SMR, Ottaiano A, Daponte A, Napolitano M, Caracò C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003, 21:767-73.
20. Ascierto PA, Palmieri G: Adjuvant therapy of cutaneous melanoma. The Lancet 1999, 353:328.
21. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-48.
22. Breslow A: Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-8.
23. Clark WH Jr, Elder DE, Guerry D 4th, Epstein MN, Greene MH, Van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15:1147-65.
24. Brownbridge GG, Gold J, Edward M, Mackie RM: Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001, 144:279-87.
25. Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 1998, 280:1036-7.
26. Leiter U, Meier F, Schittek B, Garbe C: The natural course of cutaneous melanoma. J Surg Oncol 2004, 86:172-8.
27. Waldmann V, Wacker J, Deichmann M, Jackel A, Bock M, Naher H: Prognosis of metastatic melanoma: no correlation of tyrosinase mRNA in bone marrow and survival time. Recent Result Cancer Res 2001, 158:118-25.
28. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaro, JM, Vives-Corrons JL, Grau JJ, Estape J: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996, 14:2091-7.
29. Curry BJ, Myers K, Hersey P: MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999, 17:2562-71.
30. Mellado 8, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, Estape J: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Canc Res 1999, 5:1843-8.
31. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000, 60:2253-7.
32. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, Fontanillas M, Reguart N, Domingo-Domenech JM, Montagut C, Estape J, Gascon P: Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002, 20:4032-9.
33. Abrahamsen HN, Nexo E, Steiniche T, Hamilton-Dutoit SJ, Sorensen BS: Quantification of melanoma mRNA markers in sentinel nodes: pre-clinical evaluation of a single-step real-time reverse transcriptase-polymerase chain reaction assay. J Mol Diagn 2004, 6:253-9.
34. Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch & Schmittel A, Scheibenbogen C, Heufelder K, Eggermont A, Thiel E: Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004, 10:1605-12.